Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC6A2 | P23975 | 10/20 | 0.37 |
| ▸ | SLC6A4 | P31645 | 10/20 | 0.37 |
| ▸ | SLC6A3 | Q01959 | 7/20 | 0.37 |
| ▸ | MAOA | P21397 | 1/20 | 0.34 |
| ▸ | MAOB | P27338 | 1/20 | 0.34 |
| ▸ | HTR2A | P28223 | 1/20 | 0.33 |
| ▸ | HRH1 | P35367 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16487974 | 0.78 | SLC6A2 (0.56) | SLC6A2SLC6A4SLC6A3 | |
| SCHEMBL17545825 | 0.77 | SLC6A2 (0.39) | SLC6A2SLC6A4SLC6A3 | |
| SCHEMBL10132278 | 0.74 | SLC6A2 (0.43) | SLC6A2SLC6A4SLC6A3MAOAMAOB | |
| SCHEMBL18791605 | 0.71 | SLC6A2 (0.35) | SLC6A2SLC6A4SLC6A3HTR2A | |
| SCHEMBL861946 | 0.70 | MAOA (0.44) | MAOAMAOB | |
| SCHEMBL25121801 | 0.70 | SLC6A2 (0.40) | SLC6A2SLC6A4SLC6A3 | |
| SCHEMBL31572064 | 0.66 | MAOA (0.60) | MAOAMAOB | |
| SCHEMBL5969857 | 0.66 | MAOA (0.60) | MAOAMAOB | |
| SCHEMBL16356395 | 0.66 | MAOA (0.60) | MAOAMAOB | |
| SCHEMBL17571693 | 0.66 | MAOA (0.60) | MAOAMAOB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8957075-B2 | O-GlcNAc transferase inhibitors and uses thereof | PRESIDENT AND FELLOWS OF HARVARD COLLEGE (US) | 2015-02-17 | — | — | US | disclosed |
| US-20120108605-A1 | O-GLCNAC TRANSFERASE INHIBITORS AND USES THEREOF | PRESIDENT AND FELLOWS OF HARVARD COLLEGE (US) | 2012-05-03 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120108605-A1 | O-GLCNAC TRANSFERASE INHIBITORS AND USES THEREOF | OGA, OGT, UGGT1 | SLC6A2 1715/4885SLC6A4 1669/4885SLC6A3 1442/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.